SkinBioTherapeutics PLC (SBTX)

Industry Biotechnology

This stock can be held in an Investment ISA, SIPP and Investment Account

Sell

13.00p

Buy

14.00p

arrow-up0.25p (+1.89%)

Prices updated at 12 Dec 2025, 16:26 GMT

Prices minimum 15 mins delay

Prices in GBX

SkinBioTherapeutics PLC is a life science company. The company is engaged in the development of technology to protect, manage and restore skin utilising proteins found in human microbiota.

FTSE All-Share

-0.48%

LSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Biotechnology

Chairman

Mr. Martin Braddock Hunt

CEO

Mr. Stuart John Ashman

Most recent earnings

30 Jun 2025

Fiscal year end

30 Jun 2025

Employees

41

Head office

Bath Lane

Newcastle upon Tyne

United Kingdom

NE4 5TF

+44 1914957325

Investorrelations@skinbiotherapeutics.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. Martin Braddock Hunt Non-Executive Director, Chairman	-
Dr. Catherine Denise Prescott Non-Executive Director	-
Ms. Danielle Bekker Non-Executive Director	-
Mr. Stuart John Ashman Executive Director, Chief Executive Officer	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Unicorn Asset Management Ltd	7,894,736
Unicorn AIM VCT Series 3 ORD	7,894,736
Miton Asset Management Limited	2,950,000
Premier Miton UK Smaller Companies	2,950,000

Director dealings

Date chevron-l-regular chevron-r-regular	Action
No data

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.